EyePoint Pharmaceuticals Inc expected to post a loss of 80 cents a share - Earnings Preview

EyePoint

04/08/2025 15:12

EyePoint Pharmaceuticals Inc EYPT.OQ EYPT.O is expected to  show a fall in quarterly revenue when it reports  results on August 6 for the period ending June 30 2025

The Watertown Massachusetts-based  company is expected to report a 30.1% decrease in revenue to $6.627 million from $9.48 million a year ago, according to the mean estimate from 14 analysts, based on LSEG data.

​LSEG's mean analyst estimate for EyePoint Pharmaceuticals Inc is for a loss of 80 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for EyePoint Pharmaceuticals Inc is $27.50, about 64.7% above its last closing price of $9.71

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.66
-0.66
-0.65
Beat
0.8
Dec. 31 2025
-0.47
-0.50
-0.64
Missed
-27.7
Sep. 30 2024
-0.56
-0.56
-0.54
Beat
3​
Jun. 30 2024
-0.51
-0.52
-0.58
Missed
-10.5
​​Mar. 31 2024
-0.42
-0.42
-0.55
Missed
-32.2
Dec. 31 2023
-0.46
-0.49
-0.33
Beat
32.1​
Sep. 30 2023
-0.54
-0.51
-0.33
Beat
35.7
Jun. 30 2023
0.68
0.60
-0.61
Missed
-201.9

This summary was machine generated August 4 at 14:12 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)